Jasper Therapeutics, Inc. 8-K

What Happened

• On January 8, 2026, Jasper Therapeutics, Inc. (JSPR) filed a Form 8-K to report that it issued a press release announcing positive updated clinical data from its BEACON Phase 1b/2a study of subcutaneous briquilimab in adults with chronic spontaneous urticaria (CSU) and from the open‑label extension (OLE) study in CSU and chronic inducible urticaria (CIndU).
• The company disclosed it will present the updated BEACON and OLE data on a conference call and webinar at 8:00 a.m. Eastern Time on January 8, 2026. The press release and the presentation slides were attached to the filing as Exhibits 99.1 and 99.2.

Key Details

• Filing date: January 8, 2026 (Form 8-K, Item 8.01 Other Events).
• Study: BEACON Phase 1b/2a of subcutaneous briquilimab in adult participants with chronic spontaneous urticaria (CSU).
• Extension study: Open‑label extension (OLE) data in CSU and chronic inducible urticaria (CIndU).
• Materials: Press release (Exhibit 99.1) and presentation for the Jan 8 call/webinar (Exhibit 99.2) were included in the filing.

Why It Matters

• Clinical data updates are key milestones for biotech companies; reporting “positive” updated results may be material to investors tracking clinical progress of briquilimab and Jasper’s development pipeline.
• The conference call and presentation give investors and analysts an opportunity to hear details directly from the company and assess implications for development timelines, regulatory planning, and potential future value.
• Investors should review the attached press release and presentation for the detailed data points and any management commentary supplied on the call.